On this page
What it is
Mechano growth factor, or MGF, is a name used for the IGF-1Ec splice variant and for synthetic peptides based on its distinctive E-domain. PEG-MGF attaches polyethylene glycol to an MGF-derived peptide to slow degradation and clearance in laboratory models.
That modification does not turn PEG-MGF into approved IGF-1 or prove that it reproduces the biology of the full IGF-1Ec precursor. PEG-MGF has no FDA-approved medical use, and published evidence for the specific pegylated product is much thinner than the literature on native MGF expression or unmodified E-domain peptides.
What people research it for
Activated human muscle progenitor cells in culture
Preclinical / theorizedAn ex vivo study reported that an MGF E-domain peptide increased activation and fusion potential in progenitor cells isolated from human muscle. It did not test PEG-MGF in people.
Shows a possible local repair signal
Preclinical / theorizedReviews describe increased IGF-1Ec expression after mechanical loading and injury, with preclinical signals in muscle, heart, and nervous tissue. Expression of a natural splice variant is not proof that an injected analog improves recovery.
PEGylation may prolong laboratory exposure
Preclinical / theorizedPEG attachment is a well-established drug-design method for slowing clearance, but product-specific human duration and biological activity have not been established for PEG-MGF.
Conflicting experiments limit certainty
Preclinical / theorizedA later study found that an MGF peptide up to 500 ng/mL did not increase proliferation in C2C12 cells or primary human muscle cells, while mature IGF-1 and full-length IGF-1Eb did.
How it works
Mechanical loading and muscle injury can change local IGF-1 splicing, including expression of IGF-1Ec. Synthetic MGF E-domain peptides have been studied for effects on muscle progenitor cells, but the responsible receptor and the relationship to naturally processed IGF-1 remain unsettled.
PEGylation can extend the circulation time of peptide drugs by increasing molecular size and reducing enzymatic breakdown and kidney clearance. For PEG-MGF, sellers often describe an extended half-life, but a validated human pharmacokinetic study of the marketed research peptide was not found.
What the research actually shows
A 2011 study used muscle progenitor cells isolated from healthy young and older adults. The synthetic MGF E-domain peptide activated cells and increased their fusion potential across ages. This was an ex vivo cell experiment, not a trial of PEG-MGF in people.
A 2012 review described IGF-1Ec expression after muscle stretch or overload and summarized cell and animal experiments involving a 24-amino-acid E-domain peptide. The authors also emphasized unresolved questions, including whether a free endogenous E-domain peptide is produced and which receptor mediates its reported effects.
A 2013 experiment challenged the positive cell story. MGF peptide concentrations up to 500 ng/mL did not increase proliferation of C2C12 cells or primary human skeletal muscle myoblasts. Mature IGF-1 and full-length IGF-1Eb did produce a proliferative response in the same work.
A separate 2013 study detected IGF-1Ec in pig growth-plate tissue and tested an MGF peptide in cultured chondrocytes. Adding the peptide was not associated with increased chondrocyte proliferation, another useful null result.
Animal work summarized in the review includes local muscle injury, sheep myocardial infarction, and nervous-system models. These studies concern native expression, gene constructs, or unmodified E-domain peptides. They cannot establish the effects of the pegylated retail research product in humans.
No peer-reviewed human trial was found testing PEG-MGF for muscle growth, strength, injury recovery, body composition, or any disease. Claims about a longer half-life and systemic muscle benefit remain extrapolations from general PEGylation science and preclinical MGF research.
Handling & storage
Storage at a glance
Vendor consensus- Lyophilized
- -20°C
- Keep dry and protected from light.
- Reconstituted
- 2 to 8°C
- Use within 14 days
- Conservative vendor guidance. A second supplier claims up to 28 days without a published assay.
- Light
- Protect from light and moisture.
- Room temperature
- No defensible product-specific room-temperature window was found.
- Reconstitution
- product-specified sterile diluent
- Avoid repeated freeze-thaw cycles and follow the exact product instructions.
Basis: Vendor consensus. Sources: Luxe Peptides PEG-MGF product page, Pinnacle Peptides PEG-MGF handling guide
Two checked research suppliers identify PEG-MGF as lyophilized powder and agree on frozen storage near -20°C before reconstitution. Both direct users to refrigerate prepared solution at 2 to 8°C and protect it from repeated freezing and thawing.
The suppliers disagree on the refrigerated window. One lists 14 days, while another lists up to 28 days without publishing a formulation-specific stability assay. The shorter 14-day window is shown as the more conservative vendor claim, not as pharmaceutical-grade stability evidence.
Safety & cautions
PEG-MGF lacks human safety trials. Potential concerns include unintended growth signaling, low blood sugar, fluid retention, injection or contamination risks, immune reactions to the peptide or PEG, and unknown effects on tumors or abnormal tissue growth. The frequency and severity of these risks are not defined.
Research vials can vary in identity, PEG attachment, purity, fill amount, sterility, and endotoxin burden. Safety has not been established for pregnancy, children, cancer, diabetes, cardiovascular disease, kidney disease, competitive sport, or long-term exposure.
Watch PEG-MGF prices
We'll email you when prices drop, a discount code changes, or new lab results come in for PEG-MGF. No spam — only real changes.
Frequently asked questions
Is PEG-MGF FDA approved?
No. PEG-MGF has no FDA-approved medical use.
Is PEG-MGF the same as IGF-1?
No. It is a pegylated synthetic peptide based on the E-domain associated with an IGF-1 splice variant, not mature human IGF-1.
Has PEG-MGF been tested in people?
No peer-reviewed human treatment trial was found for the pegylated research product.
Does PEG-MGF build muscle?
Cell and animal research on related MGF constructs is mixed. There is no reliable human evidence showing increased muscle size or strength from PEG-MGF.
Why is PEG attached to MGF?
PEGylation is used to slow peptide breakdown and clearance. A validated human half-life for retail PEG-MGF has not been established.
How should laboratory PEG-MGF be stored?
Checked suppliers agree on about -20°C for dry powder and 2 to 8°C after preparation. Their duration claims conflict, so product-specific instructions take priority.
Sources
- MGF E-peptide and human muscle progenitor cells
- Critical review of mechano growth factor research
- Null myoblast proliferation study
- IGF-1Ec in growth-plate tissue and chondrocytes
- PEGylation and pharmaceutical half-life review
- Luxe Peptides PEG-MGF product page
- Pinnacle Peptides PEG-MGF handling guide
Last reviewed September 17, 2026. This guide is educational and research-focused, not medical advice. PEG-MGF products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.
GO DEEPER
This guide covers one compound. We wrote the book on all 45.
The Peptide Handbook takes everything we know from testing vendors for a living and turns it into five readable books: what each compound actually does, what the evidence really says, and the honest call when the answer is "skip this one." Plus the dosing tables, calendars, and trackers that make it usable.
From the community
Ask a question →No PEG-MGF discussions yet — ask the first question and our team will answer.